Wellbutrin
Advanced Chronic Liver Disease
AstraZenecaPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Advanced Chronic Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORMAL HUMAN SERUM ALBUMIN EASL - CLIF Consortium | Phase 4 | BB |
Zinc Acexamate Hospital Universitari Vall d'Hebron Research Institute | Phase 3 | B |
Rapamycin Nottingham University Hospitals NHS Trust | Phase 2 | B |
azd2389 AstraZeneca | Phase 1 | CCC |
MIDAZOLAM AstraZeneca | Phase 1 | CC |
CAFFEINE AstraZeneca | Phase 1 | CC |
(+)-QUINIDINE AstraZeneca | Phase 1 | CC |
Same molecule, other indications
Wellbutrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →